Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
PainChek Ltd ( (AU:PCK) ) just unveiled an update.
PainChek Limited has been granted a De Novo classification by the U.S. FDA for its PainChek Adult App, which has been formally recognized as a medical device for pain assessment with a new product code ‘SGB’. This significant regulatory milestone is expected to have a material effect on the company’s securities and enhances its market positioning as a leader in pain assessment technology.
More about PainChek Ltd
PainChek Limited operates in the healthcare industry, specializing in the development of medical devices for pain assessment. Its primary product is the PainChek Adult App, which is designed to assess pain levels in individuals who may not be able to communicate effectively.
Average Trading Volume: 4,440,602
Technical Sentiment Signal: Buy
Current Market Cap: A$132.6M
Find detailed analytics on PCK stock on TipRanks’ Stock Analysis page.